View Future GrowthGedeon Richter 過去の業績過去 基準チェック /26Gedeon Richterは、平均年間14%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間9.4% 8.8%収益成長率で 成長しています。 Gedeon Richterの自己資本利益率は15.7%であり、純利益率は24.8%です。主要情報13.99%収益成長率14.47%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率8.82%株主資本利益率15.72%ネット・マージン24.80%次回の業績アップデート07 Aug 2026最近の業績更新お知らせ • Dec 12+ 4 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q4, 2024 Results on Feb 28, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q4, 2024 results on Feb 28, 2025お知らせ • Dec 14+ 6 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q1, 2023 Results on May 12, 2023Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q1, 2023 results on May 12, 2023すべての更新を表示Recent updatesお知らせ • May 30Gedeon Richter PLC Approves Dividend for the Financial Year 2025The Annual General Meeting of Gedeon Richter Plc. held on 29 April 2026 approved to pay a dividend of HUF 120,000 million in respect of the 2025 financial year. The details of the dividend payment process were published by the Company on 26 May 2026. Gedeon Richter Plc. directly and indirectly owns 3,295,804,C" series Richter common shares. The dividend on treasury shares will be distributed to those shareholders eligible for such dividend, in proportion to their number of shares. Based on the Company's current number of treasury shares, Gedeon Richter Plc. pays HUF 655.4545 dividend per share.お知らせ • Apr 08Gedeon Richter PLC announces Annual dividend, payable on June 11, 2026Gedeon Richter PLC announced Annual dividend of HUF 656.0000 per share payable on June 11, 2026, ex-date on June 03, 2026 and record date on June 04, 2026.お知らせ • Dec 12+ 5 more updatesGedeon Richter PLC, Annual General Meeting, Apr 29, 2026Gedeon Richter PLC, Annual General Meeting, Apr 29, 2026.お知らせ • Nov 28SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER).SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER) on November 27, 2025. The transaction has received approval from Antimonopoly Committee of Ukraine.お知らせ • Jul 02Gedeon Richter plc Receives European Commission Approval for Junod®? and Yaxwer®?, its Biosimilar Denosumab Products for Bone Disease and OsteoporosisGedeon Richter plc announced that the European Commission (EC) granted marketing authorization for Junod®? and Yaxwer®?, its biosimilar denosumab products. The EC decision follows the positive opinion adopted on 25 April 2025 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval marks a significant milestone as Richter's monoclonal antibody biosimilars receive EC authorization. Junod®? andYaxwer®? are approved for all indications of the reference medicines Prolia®? and Xgeva®? (Amgen), including the treatment of osteoporosis in postmenopausal women, prevention of skeletal-related events in patients with bone metastases from solid tumors, and treatment of unresectable giant cell tumor of bone. The EC approval is based on a comprehensive development program demonstrating biosimilarity to the reference products in terms of quality, safety, and efficacy.お知らせ • May 14Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp on May 13, 2025. As part of the transaction, Richter will become a major investor in Granata Bio and gain a seat on Granata Bio’s Board of Directors. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of unknown majority stake of GRANATA BIO Corp on May 13, 2025.お知らせ • Apr 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announces Annual dividend, payable on June 12, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced Annual dividend of HUF 509.0000 per share payable on June 12, 2025, ex-date on June 03, 2025 and record date on June 04, 2025.お知らせ • Dec 12+ 4 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q4, 2024 Results on Feb 28, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q4, 2024 results on Feb 28, 2025お知らせ • Dec 10Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025.お知らせ • Nov 04European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of EndometriosisGedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.お知らせ • Nov 03Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®Gedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.お知らせ • Sep 17Gedeon Richter and Sumitomo Pharma Receives Positive Chmp Opinion for Ryeqo(R) for Treatment of EndometriosisGedeon Richter Plc. ('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland GmbH ('SMPS') announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has adopted a positive opinion recommending the approval of a Type II Variation application for RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. The European Commission ("EC") will review the CHMP recommendation and a final decision on the Marketing Authorization Application is expected to be available in the coming months. The decision will be applicable to all member states of the European Economic Area. RYEQO(R) was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. This application is supported by two, 24-week, multi-national clinical studies (SPIRIT 1 and SPIRIT 2) in more than 1,200 women with moderate-to-severe pain associated with endometriosis, as well as the 80-week, open-label extension study to assess longer-term use of RYEQO(R) . Together, these data represent up to two years of efficacy and safety information with RYEQO(R). Approximately 10% of women of reproductive age have endometriosis. Many women with endometriosis-associated pain are not able to manage their pain symptoms with current treatment options, underscoring the high unmet need for this disease . Endometriosis is a disease in which tissue similar to the uterine lining is found outside the uterine cavity, commonly in the lower abdomen or pelvis, on ovaries, the bladder, and the colon. This endometrial-like tissue outside the uterus results in chronic inflammation and can cause scarring and adhesions. The symptoms associated with endometriosis include painful periods and chronic pelvic pain, painful ovulation, pain during or after sexual intercourse, heavy bleeding, fatigue, and infertility. Endometriosis can also impact general physical, mental, and social well-being. RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, andnorethisterone acetate 0.5 mg) is approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. RYEQO(R) contains relugolix, which reduces the amount of estrogen (and other hormones) produced by ovaries, estradiol (an estrogen) which may reduce the risk of bone loss, and norethisterone acetate (a progestin) which is necessary when women with a uterus (womb) take estrogen.お知らせ • Feb 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million on February 7, 2023. Geoffrey Burgess, Andrew Bab, Paul Rubin and Richard Ward of Debevoise & Plimpton LLP acted as legal advisor to Gedeon Richter. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of OC Distributors Ltd from Consilient Health on February 7, 2023.お知らせ • Dec 14+ 6 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q1, 2023 Results on May 12, 2023Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q1, 2023 results on May 12, 2023収支内訳Gedeon Richter の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:RGED.F 収益、費用、利益 ( )HUF Millions日付収益収益G+A経費研究開発費31 Mar 26925,140229,477222,12090,27331 Dec 25928,962232,335226,03691,18530 Sep 25901,323227,294232,71297,33030 Jun 25903,361221,007231,535102,74331 Mar 25878,137239,168228,090100,27831 Dec 24857,545239,244221,26899,25030 Sep 24839,601211,635207,70289,28330 Jun 24811,415229,129203,42284,35831 Mar 24798,937187,874199,58483,92431 Dec 23805,158158,850196,61978,34430 Sep 23825,94895,563201,66778,57430 Jun 23855,211123,426199,70477,38731 Mar 23844,351157,720191,46975,29031 Dec 22802,755169,076182,35075,10930 Sep 22755,061242,521165,81668,73030 Jun 22694,772198,297155,13566,48931 Mar 22657,758149,792146,77362,41931 Dec 21630,595139,626143,26161,00530 Sep 21604,708114,689139,57559,30430 Jun 21584,88799,067136,05956,07931 Mar 21566,244102,570132,52554,41831 Dec 20566,776104,683133,76653,97730 Sep 20555,12468,482134,35855,11030 Jun 20544,96468,130137,59653,74531 Mar 20527,60854,123144,86652,27331 Dec 19507,79447,135145,28148,86030 Sep 19490,66849,451144,04346,25830 Jun 19462,57636,071143,72043,36331 Mar 19453,15142,857141,65040,90331 Dec 18445,48435,348139,65440,54530 Sep 18434,07811,939140,52341,57630 Jun 18441,99718,899139,25340,76831 Mar 18445,6262,997139,41241,02731 Dec 17444,3568,885138,25639,90330 Sep 17439,82268,291137,88237,76330 Jun 17429,20766,829136,12136,31731 Mar 17413,02174,992131,93235,48931 Dec 16389,69066,200127,90335,15330 Sep 16372,68952,016122,48632,40130 Jun 16368,53944,525120,79233,58831 Mar 16366,88950,419118,31833,81331 Dec 15365,22053,863117,70734,82230 Sep 15366,63140,482117,11040,07230 Jun 15362,90339,300119,71442,380質の高い収益: RGED.Fは 高品質の収益 を持っています。利益率の向上: RGED.Fの現在の純利益率 (24.8%)は、昨年(27.2%)よりも低くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: RGED.Fの収益は過去 5 年間で年間14%増加しました。成長の加速: RGED.Fは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: RGED.Fは過去 1 年間で収益成長率がマイナス ( -4.1% ) となったため、 Pharmaceuticals業界平均 ( -4.8% ) と比較することが困難です。株主資本利益率高いROE: RGED.Fの 自己資本利益率 ( 15.7% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/22 05:27終値2026/06/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Gedeon Richter PLC 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Simon MatherBarclaysPatrick Andrew WoodBofA Global ResearchGabor BuktaConCorde Securities Ltd.15 その他のアナリストを表示
お知らせ • Dec 12+ 4 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q4, 2024 Results on Feb 28, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q4, 2024 results on Feb 28, 2025
お知らせ • Dec 14+ 6 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q1, 2023 Results on May 12, 2023Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q1, 2023 results on May 12, 2023
お知らせ • May 30Gedeon Richter PLC Approves Dividend for the Financial Year 2025The Annual General Meeting of Gedeon Richter Plc. held on 29 April 2026 approved to pay a dividend of HUF 120,000 million in respect of the 2025 financial year. The details of the dividend payment process were published by the Company on 26 May 2026. Gedeon Richter Plc. directly and indirectly owns 3,295,804,C" series Richter common shares. The dividend on treasury shares will be distributed to those shareholders eligible for such dividend, in proportion to their number of shares. Based on the Company's current number of treasury shares, Gedeon Richter Plc. pays HUF 655.4545 dividend per share.
お知らせ • Apr 08Gedeon Richter PLC announces Annual dividend, payable on June 11, 2026Gedeon Richter PLC announced Annual dividend of HUF 656.0000 per share payable on June 11, 2026, ex-date on June 03, 2026 and record date on June 04, 2026.
お知らせ • Dec 12+ 5 more updatesGedeon Richter PLC, Annual General Meeting, Apr 29, 2026Gedeon Richter PLC, Annual General Meeting, Apr 29, 2026.
お知らせ • Nov 28SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER).SIA Emteko Holding agreed to acquire Gedeon Richter UA V.A.T from Gedeon Richter PLC (BUSE:RICHTER) on November 27, 2025. The transaction has received approval from Antimonopoly Committee of Ukraine.
お知らせ • Jul 02Gedeon Richter plc Receives European Commission Approval for Junod®? and Yaxwer®?, its Biosimilar Denosumab Products for Bone Disease and OsteoporosisGedeon Richter plc announced that the European Commission (EC) granted marketing authorization for Junod®? and Yaxwer®?, its biosimilar denosumab products. The EC decision follows the positive opinion adopted on 25 April 2025 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This approval marks a significant milestone as Richter's monoclonal antibody biosimilars receive EC authorization. Junod®? andYaxwer®? are approved for all indications of the reference medicines Prolia®? and Xgeva®? (Amgen), including the treatment of osteoporosis in postmenopausal women, prevention of skeletal-related events in patients with bone metastases from solid tumors, and treatment of unresectable giant cell tumor of bone. The EC approval is based on a comprehensive development program demonstrating biosimilarity to the reference products in terms of quality, safety, and efficacy.
お知らせ • May 14Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired unknown majority stake of GRANATA BIO Corp on May 13, 2025. As part of the transaction, Richter will become a major investor in Granata Bio and gain a seat on Granata Bio’s Board of Directors. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of unknown majority stake of GRANATA BIO Corp on May 13, 2025.
お知らせ • Apr 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announces Annual dividend, payable on June 12, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced Annual dividend of HUF 509.0000 per share payable on June 12, 2025, ex-date on June 03, 2025 and record date on June 04, 2025.
お知らせ • Dec 12+ 4 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q4, 2024 Results on Feb 28, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q4, 2024 results on Feb 28, 2025
お知らせ • Dec 10Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Annual General Meeting, Apr 29, 2025.
お知らせ • Nov 04European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of EndometriosisGedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.
お知らせ • Nov 03Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®Gedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.
お知らせ • Sep 17Gedeon Richter and Sumitomo Pharma Receives Positive Chmp Opinion for Ryeqo(R) for Treatment of EndometriosisGedeon Richter Plc. ('Richter') together with Sumitomo Pharma America, Inc. ('SMPA') and Sumitomo Pharma Switzerland GmbH ('SMPS') announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") has adopted a positive opinion recommending the approval of a Type II Variation application for RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. The European Commission ("EC") will review the CHMP recommendation and a final decision on the Marketing Authorization Application is expected to be available in the coming months. The decision will be applicable to all member states of the European Economic Area. RYEQO(R) was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. This application is supported by two, 24-week, multi-national clinical studies (SPIRIT 1 and SPIRIT 2) in more than 1,200 women with moderate-to-severe pain associated with endometriosis, as well as the 80-week, open-label extension study to assess longer-term use of RYEQO(R) . Together, these data represent up to two years of efficacy and safety information with RYEQO(R). Approximately 10% of women of reproductive age have endometriosis. Many women with endometriosis-associated pain are not able to manage their pain symptoms with current treatment options, underscoring the high unmet need for this disease . Endometriosis is a disease in which tissue similar to the uterine lining is found outside the uterine cavity, commonly in the lower abdomen or pelvis, on ovaries, the bladder, and the colon. This endometrial-like tissue outside the uterus results in chronic inflammation and can cause scarring and adhesions. The symptoms associated with endometriosis include painful periods and chronic pelvic pain, painful ovulation, pain during or after sexual intercourse, heavy bleeding, fatigue, and infertility. Endometriosis can also impact general physical, mental, and social well-being. RYEQO(R) (relugolix 40 mg, estradiol 1.0 mg, andnorethisterone acetate 0.5 mg) is approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. RYEQO(R) contains relugolix, which reduces the amount of estrogen (and other hormones) produced by ovaries, estradiol (an estrogen) which may reduce the risk of bone loss, and norethisterone acetate (a progestin) which is necessary when women with a uterus (womb) take estrogen.
お知らせ • Feb 09Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million.Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) acquired OC Distributors Ltd from Consilient Health for £32.5 million on February 7, 2023. Geoffrey Burgess, Andrew Bab, Paul Rubin and Richard Ward of Debevoise & Plimpton LLP acted as legal advisor to Gedeon Richter. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (BUSE:RICHTER) completed the acquisition of OC Distributors Ltd from Consilient Health on February 7, 2023.
お知らせ • Dec 14+ 6 more updatesRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. to Report Q1, 2023 Results on May 12, 2023Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. announced that they will report Q1, 2023 results on May 12, 2023